MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1253/circj.cj-22-0093

Медицинская библиотека · Circulation journal : official journal of the Japanese Circulation Society · 2022

Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.

Watanabe Yusuke, Hayashida Kentaro, Yamamoto Masanori, Yamanaka Futoshi, Yamasaki Kazumasa, Naganuma Toru, Ohno Yohei, Yamawaki Masahiro, Morioka Nobuyuki, Mizutani Kazuki, Tada Norio, Ueno Hiroshi, Nishina Hidetaka, Izumo Masaki, Nakajima Yoshifumi, Ando Kenji, Takagi Kensuke, Kimura Tetsuya, Sugio Kumiko, Dangas George, Van Mieghem Nicolas M, Hengstenberg Christian, Chen Cathy, Jin James, Unverdorben Martin, Saito Shigeru

Рандомизированное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Japanese patients undergoing transcatheter aortic valve replacement (TAVR) are often female and have a small body size, potentially impacting bleeding risk with antithrombotic therapy. Outcomes of direct oral anticoagulant use in these patients with atrial fibrillation (AF) need to be clarified.

METHODS AND

RESULTS

This prespecified analysis included Japanese patients from ENVISAGE-TAVI AF, a prospective, randomized, open-label, adjudicator-masked trial that compared treatment with edoxaban and vitamin K antagonists (VKAs) in patients with AF after TAVR. The primary efficacy and safety outcomes were net adverse clinical events (NACE; composite of all-cause death, myocardial infarction, ischemic stroke, systemic embolic event, valve thrombosis, and International Society on Thrombosis and Haemostasis [ISTH]-defined major bleeding) and ISTH-defined major bleeding, respectively. Intention-to-treat (ITT) and on-treatment analyses were performed. Overall, 159 Japanese patients were enrolled (edoxaban group: 82, VKA group: 77) and followed for on average 483 days. Mean patient age was 83.8 years; 52.2% were female. In the ITT analysis, NACE rates were 10.9%/year with edoxaban and 12.5%/year with VKA (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.38-1.90); major bleeding occurred in 8.9%/year and 7.3%/year, respectively (HR, 1.17; 95% CI, 0.45-3.05). In edoxaban- and VKA-treated patients, rates of ischemic stroke were 1.8%/year and 1.0%/year, respectively; fatal bleeding rates were 0.9%/year and 2.0 %/year. On-treatment results were similar to ITT.

CONCLUSIONS

In Japanese patients with AF after successful TAVR, edoxaban and VKA treatment have similar safety and efficacy profiles.

Для цитирования: Watanabe Yusuke, Hayashida Kentaro, Yamamoto Masanori, Yamanaka Futoshi, Yamasaki Kazumasa, Naganuma Toru, Ohno Yohei, Yamawaki Masahiro, Morioka Nobuyuki, Mizutani Kazuki, Tada Norio, Ueno Hiroshi, Nishina Hidetaka, Izumo Masaki, Nakajima Yoshifumi, Ando Kenji, Takagi Kensuke, Kimura Tetsuya, Sugio Kumiko, Dangas George, Van Mieghem Nicolas M, Hengstenberg Christian, Chen Cathy, Jin James, Unverdorben Martin, Saito Shigeru. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.. Circulation journal : official journal of the Japanese Circulation Society. 2022. DOI: 10.1253/circj.cj-22-0093.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.